Answers are grounded in this paper and cite their sources.
Tirzepatide, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide, is increasingly evaluated and used to manage metabolic disorders.It was first approved for the treatment of type 2 diabetes mellitus and subsequently for weight management and obstructive sleep apnea.Semaglutide, an isolated GLP-1 analog, was associated with significant improvements, culminating in its approval for selected patients with metabolic dysfunction-associated steatohepatitis (MASH).This narrative review analyzes and summarizes the published literature on the utility of tirzepatide in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/MASH.We conducted a comprehensive PubMed search to identify relevant literature and extracted pertinent information to prepare the manuscript, with an emphasis on tirzepatide pharmacology, pharmacokinetics, dosing, its utility in metabolic liver diseases, and adverse drug reactions.Published literature to date has consistently reported improvements in multiple facets of MASLD/MASH, including improvements in transaminase levels and steatosis/steatohepatitis on magnetic resonance imaging and histology.The side-effect profile was largely comparable to that of semaglutide.The most frequent side effects include gastrointestinal intolerance such as nausea, vomiting, abdominal pain, and diarrhea.Biliary and pancreatic adverse reactions are less frequent.A major limitation is that currently available data on tirzepatide in MASH/MASLD come from subanalyses of studies on other metabolic diseases that include MASH/MASLD.Furthermore, the optimal dosing, duration, and long-term effects of tirzepatide for hepatic benefits remain unclear.Therefore, further confirmation and validation are needed from large-scale, multicenter, randomized controlled trials in patients with MASH/MASLD.Ongoing trials of tirzepatide in patients with MASH are expected to shed further light on this perspective.
No takes yet. Share an insight, caveat, or question.
Zacharia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: